Before the March 28 announcement of Takeda’s interest in buying Shire, the focus of Shire’s first quarter earnings call was expected to be the initial reporting of financial results for rare disease and neuroscience as separate units. Sales for the former grew, but declined for the latter.
The possible acquisition by Takeda Pharmaceutical Co. Ltd. was top of mind for everyone involved in Shire PLC’s first quarter 2018 earnings call April 26, but under UK takeover law the company could not discuss the situation, although that didn't stop one analyst from asking CEO Flemming Ornskov how shareholders feel about the possible buyout.
Since first publicly disclosing its interest in acquiring Shire on March 28, Takeda has made five offers, increasing incrementally from...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
